Company Reports / Daiichi Sankyo

COMPANY: Daiichi Sankyo

INDEX RANK: 9th

Total Impact Score: 417,932.91

Daiichi Sankyo is ranked 9th place in our index for 2015. Daiichi Sankyo’s drugs have a total impact score of 417,932.91. Daiichi Sankyo treats two diseases in our model - XDR-TB and MDR-TB - with two total drugs - Levofloxacin (Lfx) and Ofloxacin (Ofx). Daiichi Sankyo receives credit for two treatments against XDR-TB - Levofloxacin (Lfx) and Ofloxacin (Ofx). These two drugs averted 13,294.90 of the total DALYS for XDR-TB, which is 18.75% of the worldwide DALYs that we estimate would have been lost due to XDR-TB in 2015 in the absence of effective treatment. Daiichi Sankyo’s drug portfolio placed it 2nd in terms of total averted DALYs for XDR-TB. Daiichi Sankyo receives credit for one treatment against MDRTB - Levofloxacin (Lfx). This one drug averted 404,638.01 of the total DALYS for MDR-TB, which is 20.23% of the worldwide DALYs that we estimate would have been lost due to MDR-TB in 2015 in the absence of effective treatment. Daiichi Sankyo’s drug portfolio placed it 2nd in terms of total averted DALYs for MDR-TB.

Company Score Breakdown:

Key Drugs

LEVOFLOXACIN (LFX)

Levofloxacin (Lfx), a fluoroquinolone antibiotic, is a Group A second line drug used in the treatment of rifampicinresistant and multidrug-resistant tuberculosis. It has a good safety profile and is relatively highly effective against TB. Side effects include hallucinations and diarrhea. Lfx was patented by Daiichi Sankyo in 2006.

OFLOXACIN (OFX)

Ofloxacin (Ofx), a fluoroquinolone antibiotic, has widely been replaced as a treatment for TB by later generation fluoroquinolone antibiotics. Due to its toxicity, its primary use is now as an ophthalmic in ear and eye drops. Ofloxacin was patented by Daiichi Pharmaceutical Co., Ltd. in 1980.

Company Information

Daiichi Sankyo is the second largest pharmaceutical company in Japan and was founded in 2005 by the merger of Sankyo Co. and Daiichi Pharmaceutical. The company is currently ranked 17th in sales worldwide and holds both the German biotech company, U3, and the American biotech company, Plexxikon. Daiichi Sankyo focuses on prescription drug manufacturing and research and development that focuses on oncology, cardiovascular-metabolics, and pain management. They have been funding the Global Health Innovative Technology Fund since 2013 to promote the development of drugs for infectious diseases in developing countries. Significant drugs include: Azor®, Benicar®, and Effient®. In 2017, their revenue was $8.48 billion dollars with operations in over 50 countries and over 14,400 employees.

Company Report PDF

CONTACT US © 2017 GLOBAL HEALTH IMPACT